Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its biopharma operations include ANB033, a CD122 antagonist for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter for rheumatoid arthritis; and ANB101, a BDCA2 modulator. Anaptys has also discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.

On March 27, 2026, Anaptys' Board of Directors approved the spin-off of First Tracks Biotherapeutics (Nasdaq: TRAX). For specific First Tracks Biotherapeutics SEC filings, access the SEC EDGAR system here.